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ABSTRACT 
 
 
This project presents a new method of developing genomic signatures of 
carcinogenicity and offers a way of understanding the mechanisms of action for 
environmental chemicals, and a method for characterizing the carcinogenicity of said 
chemicals. Specifically, this project is an effort to “use a high-dimensional assay that 
allows for the genome-wide characterization of the transcriptional response to chemical 
exposure at a cost unmatched by other technologies, paired with the biological and 
computational expertise necessary to maximally leverage the information produced by 
the assay.”11 The primary aim of these preliminary experiments was to determine if the 
protocol of treating the cells at Boston University under strict IBC-approved conditions 
and then gathering data at the Broad Institute (Boston, Massachusetts) is a reasonable 
technique for obtaining high-throughput genomic signatures with chemicals of unknown 
carcinogenicity status. The results of this experiment demonstrate this methodology for 
obtaining genomic signatures has the potential to be a replicable, high-throughput 
procedure to assist in creating a “carcinogenome” database (CGDB).
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INTRODUCTION 
 
 
Cancer is a disease which continues to threaten the well-being of individuals 
across the world. In America alone, 21% of the population will die from cancer.
1
 Since 
genetic factors have been found to contribute only as a minor cause of cancer mortality, 
much focus has been placed on studying environmental influences on the disease.
1-3 
The 
field of environmental chemicals and cancer research is one in which there is little 
completed research. The 2010 Presidential Cancer Panel recognizes this field as a 
potential area for understanding cancer causation by environmental chemicals through the 
use of high-throughput technologies.
2,4
  
 
The Need for Models of Carcinogenicity 
Current research on carcinogen testing involves costly and time-consuming rodent 
studies of individual chemicals. Of the approximately 80,000 chemicals in commercial 
usage, only 1,500 have been tested using this standard.
5-7
 This model is also limited 
because it is difficult to determine the result of mixtures of chemicals and carcinogenic 
effect. Previous studies have demonstrated the carcinogenicity of chemicals can be 
characterized by understanding chemical-induced gene mutations, chromosomal 
aberration and aneuploidy.
8-10
  
This project presents a new method of developing genomic signatures of 
carcinogenicity and offers a way of understanding the mechanisms of action for 
environmental chemicals, as well as a way of characterizing the carcinogenicity of said 
chemicals. Specifically, this project is an effort to “use a high-dimensional assay that 
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allows for the genome-wide characterization of the transcriptional response to chemical 
exposure at a cost unmatched by other technologies, paired with the biological and 
computational expertise necessary to maximally leverage the information produced by 
the assay.”11 
 
Proposed Method for a Predictive Model of Carcinogenicity  
 The ability to create a carcinogenome requires a high-throughput technology such 
as one developed by the Broad Institute (a collaborative research institution between MIT 
and Harvard University, Boston, Massachusetts) through the NIH Common Fund’s 
LINCS program. This technology, the “L1000”, uses correlations between data obtained 
with a limited set of targeted genes and the more traditional microarray technology to 
characterize over 20,000 genes in the human transcriptome into 1,000 gene clusters 
represented by  “landmark” genes.15 A landmark gene is representative of a specific gene 
cluster, and 1,000 landmark gene transcripts on Luminex beads (which make up the 
foundation of the L1000 technology) accurately predicts 80% of the gene connections 
discovered by traditional, more-expensive, and less high-throughput means (Figure 1). 
The 1,000 landmark genes were selected on the basis of principal component analyses 
(PCA) of data from the Gene Expression Omnibus (GEO).
23 
 The Broad Institute anticipates that a reduced representation transcription paired 
with a computational inference model is able to accurately create a genome-wide 
expression profile. With this technology, the Broad anticipates working toward the 
creation of “CMaps,” or “Connectivity Maps” on a high-throughput scale to develop a 
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primary screening library of “perturbagens” complete with numerous different cell lines 
and treatment parameters.
21 
 The three main applications the Broad foresees for this 
technology are: 1) the creation of a database with which scientists can develop more 
educated and directed hypotheses, 2) understanding disease or gene-specific signatures 
and 3) the creation of a chemical library-scale connectivity map in order to understand 
gene expression as a sensor of bioactivity.
21
  
Whereas the traditional microarray, e.g. an Affymetrix chip, costs approximately 
$500/sample, the L1000 costs approximately $5/sample and can be run on 384 well plates 
(with a different chemical in each well) and thereby is able to provide “80% of the 
information at 1% of the cost”. The Broad Institute has the technological capacity to run 
over 100 plates per week. As of October 2012, the Broad Institute has over 500,000 
genomic profiles for 10 different cell types of 4,000 small molecules, 3,000 Open 
Reading Frames (ORF), and 9,000 shRNAs (3 constructs of each shRNA).  
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Figure 1. L1000 Computational Inference Potential. Based on the 1,000 Landmark 
genes, the Broad Institute is able to predict inferred connections. (Image courtesy of 
Aravind Subramanian, Ph.D.).
23 
 
Specific Aims
 
 The focus of this research project is to determine the efficacy and efficiency of the 
development of a predictive genomic signature model for carcinogenicity (a 
“carcinogenome”) which will quantitatively characterize the degree of carcinogenicity of 
specific environmental pollutants. Specifically, we will develop a computational 
predictive model of carcinogenicity by analyzing the effect that a specific chemical has 
on upregulating or downregulating genes. A carcinogenome database (CGDB) could 
ultimately be used to provide a carcinogen predictive model for any given chemical in the 
database.  
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In order to determine the feasibility of this model, we will first study the effects of 
approximately 100 different chemicals (which will include compounds with a known 
carcinogenicity status) in collaboration with The Broad Institute (Boston, Massachusetts), 
on immortalized cell lines. We will test the ability of the expression profile determined 
from this technology to correctly predict the known carcinogenic status of the chemicals 
being tested in the pilot experiment by determining the efficacy, sensitivity, and 
specificity. 
Because the Broad Institute does not have the institutional capacity to treat with 
carcinogenic compounds, the Sherr Laboratory, a BSL2 laboratory with standard 
operating procedures for handling multiple carcinogens at once, will prepare and dose the 
cells at Boston University using high through-put robotics.  This collaborative effort will 
be important to insure the reliability of the L1000 in representing outcomes of the entire 
genome and to demonstrate that the chemical carcinogenicity can be predicted by 
computational analyses. 
 
For this initial project specific aims will be: 
1.) To run quality control checks with the Boston University Core facility 
instruments to insure a minimal level of error in plating the cells, dosing the 
compounds, and washing the carcinogen-containing media from the plates 
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2.) To prepare cell lysate for genomic signatures at Boston University: 
a. for 52 carcinogen and 51 non-carcinogen compounds  
b. in four different cell lines 
c. at two different dosing timepoints (6 hours and 24 hours) 
3.) To determine if the protocol for treating the cells at BU and then gathering data at 
the Broad Institute is a reasonable technique for obtaining high-throughput 
genomic signatures with chemicals of unknown carcinogenicity. 
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METHODS 
Introduction 
 Protocols for the pilot experiments were obtained from Xiaodong Lu, Ph.D., at the 
Broad Institute. Cell culture and treatment work was completed at the Boston University 
High Throughput Core Facility (Boston, Massachusetts) and L1000 plate reading was 
completed at the Broad Institute (Boston, Massachusetts) July 2011-February 2013. 
 
Compound Selection 
 Compounds to be included in this study were prioritized in collaboration with the 
Environmental Protection Agency (EPA), the National Toxicology Program (NTP), and 
the National Institute of Environmental Health Sciences (NIEHS), specifically in 
collaboration with Raymond Tice, Ph.D. and Scott Auerbach, Ph.D. These compounds 
were drawn from ToxCast (www.epa.gov/ncct/toxcast/chemicals.html) and the 
International Agency for Research on Cancer (IARC, 
http://monographs.iarc.fr/ENG/Classification) databases and were selected based upon 
known carcinogenicity status, mode of action, and degree of presence in the environment. 
Table 1. Carcinogenic and non-carcinogenic compounds on pilot plate 
Compound Classification Number of Compounds 
Non-Carcinogen 51 
Carcinogen 52 
TOTAL 103 
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Of the chemicals included in the preliminary compound plate, 51 compounds are 
known to be non-carcinogenic and 52 chemicals are known to be carcinogenic (Table 1). 
Each chemical is characterized based upon it’s mode of action as a direct genotoxic agent 
(such as an alkylating agent), an indirect genotoxic agent (such as topoisomerase 
inhibitors), or as a non-genotoxic/receptor mediated chemical (such as AhR-, PXR-, 
PPAR-, and oxidative stress-inducing compounds). Compounds which are negative and 
positive by the Ames test are also included as another means of comparison in 
carcinogenicity classification.
9,12
 Additionally, because the Sherr laboratory has 
knowledge and experience with Aryl Hydrocarbon Receptor (AhR) ligands, these 
chemicals are included in the compound listing.
13,14
 The AhR plays an important role in 
chemically-induced cancers. The complete listing of compounds included in this pilot 
experiment is found in Appendix 1.  
Optimal dosage for each compound was determined by published in vitro toxicity 
data, and by preliminary toxicity testing performed in the Sherr Laboratory. Compounds 
were included in randomized triplicate on the 384 well-plate. 
 
Cell line selection 
 Cell lines were selected based on lines the Broad Institute has successfully 
collected genomic signatures of cells exposures to a library of drugs and other 
compounds. Additionally, cell lines were selected based on applicability to environmental 
chemical-induced cancer from previous studies. The four cell lines used in this pilot 
experiment include: MCF7 (human epithelial breast cancer cell line from mammary 
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gland adenocarcinoma), HA1E (human embryonic kidney cell line), HMELz (human 
breast epithelial cell line), and PC3 (human epithelial prostate cell line from a grade IV 
adenocarcinoma). Cells were generously provided by Xiaodong Lu, Ph.D., from The 
Broad Institute (Boston, Massachusetts).  
 
PROTOCOL 
 
Initial Quality Control Tests 
 
Quality control tests were completed before the initial pilot experiment to ensure the 
accuracy and precision of the procedure. These tests included: 
1.) Precision of robotic versus hand pipetting of cells.  
1,000 MCF7 cells were plated into 252 wells of a 384 well-plate using a cell 
plating robot (ThermoScientific, Multidrop Combi Reagent Dispenser, 5840300) 
or by hand using an electronic, multi-channel pipet (ThermoScientific, 
FinnPipette Novus Multichannel Pipetter, 14-387-115). Cell counts and 
distribution were compared using an image-based microplate reader (Cyntellect, 
Celigo Image-Based Microplate Reader, 77816883) 
2.) Precision of core high-throughput dosing robot (Apricot 550 Liquid 
Handling System).  
Fluorescein isothiocyanate (FITC) was plated as a fluorescent dye to confirm 
even distribution on the compound plate, and was used to dose 2,000 MCF7 cells 
in five 384 well-plates. The final concentration in the dosed cell plate was 
determined with a plate reader (Tecan, SpectraFluor Plus) and even distribution of 
dosing was monitored via analysis of FITC fluorescence in each well.  
10 
 
3.) PBS wash cell viability test.  
A plate washer (Bio-Tek  ELx50 Auto Strip) was used to aspirate media from the 
wells dosed with carcinogens and the plates were washed three times with PBS 
before harvesting the RNA from the wells. PBS was added by electronic, multi-
channel pipet ThermoScientific, FinnPipette Novus Multichannel Pipetter, 14-
387-115). Cells were counted with Cell Titer Glo (Promega, PR-G7570) both 
before and after the PBS washes to determine viability differences due to the 
washes. 
 
Cell Preparation 
 
Cells were trypsinized in cell culture dishes prior to being quenched using FBS-
containing media. Trypsinized cells were centrifuged at 1,000 rpm for four minutes, the 
medium was aspirated and 5 mL of fresh media was dispensed onto the cell pellet. 19 
milliliters of media was added to the cell pellet mixture and mixed to create a uniform 
suspension. The resuspended cells were counted and viability was quantified with trypan 
blue. For the cell plating in the 384-well plate, 3,500 cells were plated per well in 45uL of 
medium using the Combi Reagent Dispenser (ThermoScientific, Multidrop Combi 
Reagent Dispenser, 5840300). Cells were maintained at room temperature for 20 minutes, 
and then placed in stacks of 5 plates in the incubator at 37 degrees Celsius and 5% CO2.  
The plates were incubated for 24 hours.  
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Cell Treatment 
Next, the compound plate with carcinogens and non-carcinogens was prepared. 
Compounds were obtained from the National Toxicology Program (NTP) or from Sigma-
Aldrich. Compounds were prepared at 10mM, and 10uL of each compound was placed in 
triplicate on the plate. DMSO was used as a control for the compounds, as compounds 
were dissolved in this solvent. The compound plate was covered with an aluminum plate 
sealer (Bio-Rad, 181-4040) and centrifuged before use. At the time of cell dosing, the 
compound plate and the plated cell plate were placed on the Apricot 550 Liquid Handling 
System along with a dilution plate which contained 99uL of 10% RPMI media. The robot 
transferred 1uL of compound to 99uL of media and mixed the compound with the media 
three times to create a uniform solution. The dilution plate was then sealed with a foil 
plate seal (Bio-Rad, 181-4040) and spun down in a centrifuge for one minute at 
1,000rpm. Next, the robot transferred 5uL of the compound diluted in the RPMI media 
onto the plated cells. Finally, the plates were placed in the incubator and sets were 
harvested at 6 and 24 hour timepoints after the initial dosage.  
12 
 
 
 
Figure 2. Protocol for cell dosing. Robot will pick up compounds from compound plate, 
and then transfer to the dilution plate. Next, the dilution/compound mixture will be added 
to 384-well plates with cells. 
 
Cell Lysate Harvest 
For the harvest, media was removed by a plate washing robot (Bio-Tek Instruments, 
ELx50 Auto Strip washer) and washed with PBS (Mediatech, MT-20-030-CV) three 
times. Next, 35uL of TCL buffer (Qiagen, cat#: 72271) was added and cell lysis plates 
incubated at room temperature for 30 minutes, then stored in the -80
o
 freezer. 
 Cell Titer Glo was used to check viability of cells at the 24 hour timepoint on a 
parallel test plate. 10uL of Cell Titer Glo was added to each well, and read on a plate 
reader after 15 minutes.  
Contains all carcinogens and 
Non-carcinogens in triplicates 
(at all optimal concentrations) 
Contains 99uL of 
media 
 
Robot will add 1uL 
From the compound 
Plate into the dilution 
Plate, and will mix 3 
times 
Robot will add 5uL of solution from 
the dilution plate to 45uL media in 
each of the experiments. 
 
Robot will only return to the dilution 
plate to dose new plate 
 
4 cell lines x 2 timepoints x 3 
replicates=24 plates total 
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 Cell lysate plates were transferred to the Broad Institute. At the Broad Institute, 
“poly-A mRNAs [were] captured from the lysates on oligo-dT-coated plates, and the 
1,000-plex ligation-mediated amplification procedure [was] performed. The samples 
were detected on Luminex FlexMap-3D instruments and 2 x 500-color Luminex beads, 
using two different bead concentrations as a means to obtain 1,000 analytes from 500 
bead colors.”11,16   
This ligation-mediated amplification process uses the mRNA transcripts from the 
lysates and amplifies the gene transcripts of interest using probe pairs to detect gene 
transcript levels by the Luminex Flexmap system (Figure 3).
24
 This technology uses 
microspheres which have different dyes and fluorophores for each genomic transcript of 
interest.
24 
The Luminex software program detects each of the individual microspheres bound to 
a specific sample.After standardized quality control measures, the data were transferred 
to Boston University via file transfer protocol (FTP). 
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Figure 3. xMAP Technology as described by Luminex
24 
16 
 
 
Figure 3. xMAP Technology as described by Luminex
24 
plate
22  
Figure 4. Flow diagram of Broad Institute dataset generation from scanned lysate 
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Data interpretation 
Stefano Monti, Ph.D. (Boston University) analyzed the dataset generated by the 
Broad Institute with a [20,000 x N]data matrix using computational inference models in 
addition to classification algorithms (Weighted voting, k-nearest neighbors, Support 
Vector Machines, etc).
11,17,18,20
 Biological interpretation was based on the Cancer Cell 
Line Encyclopedia (http://www.broadinstitute.org/ccle) and the Connectivity Map 
(www.broadinstitute.org/cmap).  
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RESULTS 
Initial Quality Control Test Results 
1.) Precision of Robot-assisted versus hand-pipeting of cells.  
 When the cell plating robot results are compared to that of the electronic multi-
channel plating results, the average number of cells plated manually (482.04 cells/well) 
was significantly less than that plated by the robot (746.33 cells/well), (Table 2). The 
robot approached the actual counted and calculated number of cells per well (1,000 
cells/well). It was decided to plate the cells for the pilot experiments with the mechanical 
cell plater because of the higher average number of cells distributed in each well. These 
values only give an estimate of the number of cells in each well, as the image-based 
microplate reader (Cyntellect Celigo) used to count the cells also contributes a source of 
error to these presented values. 
 
Table 2. Robot versus hand-pipetting accuracy for plating cells in 384-well plate 
  Hand Pipet 
 (cell counts) 
Robot 
 (cell counts) 
Average 482.04 746.33 
Minimum 193 202 
Maximum 1043 1660 
Standard 
Deviation 
161.15 178.22 
Number of wells 252 252 
Standard Error 10.15 11.21 
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2.) Precision of Apricot dosing robot.  
The FITC plated on compound plate was added to a dilution plated and used to 
distribute 2,000 MCF7 cells into 5 different 384 well-plates. The final concentration in 
the dosed cell plate was determined with a plate reader (Tecan, SpectraFluor Plus) and 
even distribution of dosing was monitored. 
Figure 5 displays a visual representation of the dosing of the 5 different 384 well-
plates used for this test. If the fluorescence reading of FITC was greater than 650, the 
well was conditionally formatted as red. If the fluorescence reading of the well was less 
than 450, the well was conditionally formatted yellow. As demonstrated by the visual 
representation of the distribution of the higher and lower ranges of the fluorescence 
readings, the very first plate dosed had the greatest variation. Because of this, for the pilot 
experiments, a primary “test” plate was dosed, but discarded to eliminate the variation in 
the first dosed plate. Outer wells of the 384 well-plate were not used for the pilot 
experiment due to edge effects and concerns regarding evaporation of media around the 
corners of the plates. 
The variations in dosing for the plates was determined to be randomized, and not 
associated with specific pins on the Apricot robot, and was within a reasonable range of 
error (10%) for these initial tests. This percent error threshold was based on Apricot 
company recommendations for high-throughput experiments. 
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Figure 5. Distribution of even dosing of compounds by Boston University core 
instruments. Plates 1-5, 384-well plates. Measurement >650=red; cell counts 
<450=yellow  
21 
 
 
3.) PBS Wash Viability Tests 
 
 The results of the PBS wash cell viability tests demonstrate that PBS washing 
reduces the number of cells in each well by approximately 25% (Table 3B). This may be 
due to the mechanical action of the Auto Strip washer (Bio-Tek Instruments, ELx50 Auto 
Strip washer), and the additional stress of adding PBS to the cells three times. Cell Titer 
Glo (Promega, PR-G7570) viability tests demonstrate the PBS washes increase variation 
in cell counts between the different plates (a 7.4% error rate between plates), (Table 3A). 
This step is necessary because the cell plates must be washed with PBS to rid the plate of 
the toxic media before transferring the plate to the Broad Institute. Consequently possible 
error introduced by the additional washing step must be taken into consideration when 
interpreting the results. In an effort to reduce the error, two PBS wash steps instead of 
three were used for the initial pilot tests. 
Table 3A. PBS washes cell viability Plates 1-5 
 
 
 
 
  
PBS Washed 
Plate 1 
PBS Washed 
Plate 2 
PBS Washed 
Plate 3 
Non-washed 
Plate 4 
Non-washed 
Plate 5 
Average 2.07 2.62 0.45 3.01 3.18 
SD 0.67 0.92 0.17 1.03 1.07 
SE 0.03 0.05 0.01 0.05 0.05 
Min 0.49 0.66 0.21 0.90 0.91 
Max 4.88 7.30 1.44 7.63 7.32 
22 
 
 
  
AVERAGE 
PBS 
WASHED 
PLATES 
AVERAGE 
NON PBS 
WASHED 
PLATES 
All 
Plates 
 Average 1.71 3.09 2.26 
 SD 0.58 1.05 0.37 
 SE 0.03 0.05 0.17 
 Min 0.21 0.90 0.21 
 Max 7.30 7.63 7.63 
      Table 3B. PBS washes versus no PBS washes cell viability comparison table 
 
RESULTS OF INITIAL PILOT EXPERIMENT 
General Findings 
 These preliminary experiments provide data for correlations between the triplicate 
compounds for plates dosed at the Broad Institute compared to those dosed at Boston 
University. Additional correlations for comparability were analyzed between replicates 
for the PBS washed plates versus the non-washed control plates. 
 In another set of plates, one plate was dosed and harvested as cell lysate, then 
transferred to the Broad, as indicated in the protocol. A second plate went through the 
cDNA extraction protocol at BU’s core as well, so that the reverse transcriptase step 
leading up to the PCR reaction was also completed at Boston University. Correlations 
between these differences in protocol were also compared. 
 It is evident from these results that the genomic signature strength is not strong 
enough to record a conclusive reading for the majority of the compounds from these 
preliminary runs. For both the washed and non-washed plates, those dosed at BU and at 
those prepared at the Broad Institute, and for the RNA extraction plate compared with the 
23 
 
cDNA prepared plate, approximately 25% of all the compounds had detectable genomic 
signatures.  
 In general, there was more correlation between the plates which did not undergo a 
PBS washing as compared with those that were washed 3 times. There was stronger 
correlation between the triplicates in cells treated at the Broad Institute as compared with 
Boston University. Additionally, the correlation was strong in the RNA plates as 
compared with the cDNA extraction plates, both which were prepared at Boston 
University. 
 
Boston University-treated versus Broad-treated cell correlations 
 As indicated in Figures 7 and 8, for the RNA lysates prepared at Boston 
University, the signature strength is lower than that of the Broad’s signature strength. 
Interestingly, the washed versus non-washed conditions did not make a difference in 
signature strength. From Figure 8, correlation between replicates (the three randomized 
wells on the 384-well plate dosed with the same compound) was evident. However, the 
threshold level was unable to provide a strong genomic signature for the lysed cells for a 
significant number of the compounds. 
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Figure 7. Mean Signature Strength for washed and non-washed compounds at the Broad 
Institute and Boston University. Comparison of the genomic signature reading levels for 
plates washed with PBS, and plates which were not washed with PBS. 
25 
 
 
Figure 8. Signature Strength Visualization for different treatment facilities and PBS 
washing conditions. Comparsion of the genomic signature readout for plates washed with 
PBS, and not washed with PBS at both The Broad Institute, and Boston University. 
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cDNA extraction at Boston University versus Broad 
 As demonstrated from Figure 6, compounds which had the reverse transcriptase 
cDNA extraction step performed at the Boston University facility (post_wash: gold 
triangles on the figure) had a statistically significant lower signature signal than 
compounds which had the cDNA extraction performed at the Broad Institute 
(demonstrated by the red circles). Additionally, the data presented in Figure 5 
demonstrate the methods preformed at the Broad Institute gave a higher signal result than 
at Boston University.  
 The differences in signature signals in data generated at the two locations may be 
attributed to the precision of the high throughput robots performing the cDNA extraction. 
This source of error would be amplified by using the Boston University Apricot liquid 
handler high-throughput robot for additional steps. 
 The treatment of the cells must take place at Boston University because of the 
high hazard carcinogen work, but the cDNA extraction may be performed at either 
facility. In the future, cDNA extraction will be performed at The Broad Institute because 
the data demonstrate stronger signature signals are obtained following extraction at The 
Broad Institute. 
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Washed versus non-washed cells correlations 
 Figures 6 and 7 display the comparison between plates which had been washed 
three times with PBS versus treated cells with did not receive the wash steps, for which 
RNA was harvested immediately. 
 From Figure 6 (data from plates run at The Broad Institute), the median signature 
strength for the treated cell lysates was 6.2 for plates which were not washed with 
Phosphate Buffered Saline, and 5.5 for plates which underwent the three time wash step. 
At Boston University, the median signature strength was 4.3 for the washed plates, and 
4.0 for the non-washed plates. These correlations are presented in an alternate form in 
Figure 7, which includes the range of the different signature strengths for each facility, 
and for each condition.  
 The wash step for this high-throughput experiment is unavoidable, because it is 
necessary to ensure the carcinogens used to treat the cells are removed before harvesting 
the plate for RNA. The results of the washed and non-washed cells from The Broad 
Institute demonstrate that the wash step is reducing the strength of the signature. This is 
likely attributed to each wash lifting some of the treated, adherent cells from the plate. 
Reduced cell number before RNA preparation could cause a reduced signature capture. In 
the future, two PBS washes instead of three PBS washes will be used to reduce the 
reduction in signature strength induced by the wash step in addition to increasing the 
original number of cells in each well. 
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BU versus Broad F-Statistic Correlations 
Figure 8 demonstrates the correlations between triplicates for cell treatment plates 
at Boston University. Correlation between triplicates compared with non-triplicates was 
statistically significant. Figure 9 displays that correlation between replicates as compared 
to non-replicates for cDNA extraction protocol-treated plates at Boston University was 
significant. In a comparison of Boston University-treated cell plates with plates which 
were washed, statistical significance was reached between replicates versus non-
replicates (Figure 10).  
F-Statistic tests were performed to analyze the degree of variance from normality 
for the treated cell lysate plates. Greatest deviation was demonstrated with Broad-treated 
and washed cells (Figure 11). Variation was reduced with washed lysate plates as 
compared with non-washed lysate plates (Figure 11).  
 These data demonstrate a reduced degree of error is necessary to see increased 
deviation from normal distribution, and consequently stronger signatures. 
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Figure 9. BU cDNA extraction 
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Figure 8. BU treated versus Broad treated cells 
 
Figure 10. BU-treated compounds washed versus non-washed 
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Figure 11. BU versus Broad F-Statistic distributions  
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DISCUSSION 
Specific Aims 
 These experiments achieved the specific aim of insuring quality control checks 
within the Boston University Core facility instruments for future genomic screens. From 
these experiments, we can estimate a total 10% mechanical error from the cell plater, the 
Apricot dosing error, and from the PBS washes. Care was taken to minimize the error 
from these three sources and in the future it will be important to seek alternative methods 
for reducing the error even further. Even though the error is 10% within the core 
facilities, this error becomes magnified with the L1000 reactions. 
 The second aim of creating strong genomic signatures through the use of Boston 
University’s core equipment shows promising results. Although there is significant 
variability between compounds dosed at the Broad Institute versus Boston University and 
between the PBS washed and non-washed test runs, it is believed these differences would 
be minimal in capturing a signal if the genomic signature has a significantly strong initial 
reading. 
The third aim of this project, determining if the protocol of treating the cells at 
BU and then gathering data at the Broad Institute is a reasonable technique for obtaining 
high-throughput genomic signatures with chemicals of unknown carcinogenicity status, 
appears promising based on the preliminary data. Although there are significant sources 
of error with the Boston University core equipment and the added wash step, future 
minimization of this error may be achieved through improvement of the core facility 
equipment (updates to robotic components, calibration of instruments more precisely, 
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purchase of newer equipment). Such changes will likely result in stronger genomic 
signature readouts from the L1000. 
 
Future Experiments and Impact 
The results of these experiments demonstrate that a methodology for obtaining 
genomic signatures has the potential to be a replicable, high-throughput procedure to 
assist in creating a “carcinogenome” database (CGDB). The creation of such a database 
will elucidate environmental drivers for cancer and could serve as the basis for exposure 
risk models for cancer development. Additionally, such a reference would provide the 
exposure mechanisms of action (MoA), pathways of carcinogenicity (PoC), and 
signatures of carcinogenicity (SoC), which further assist in developing drug targets and 
potential cancer therapeutics.  
A CGDB would provide a prediction model for labeling a chemical as a 
“carcinogen” or “non-carcinogen” and would serve as a measurement for the safety level 
of the over 80,000 chemicals in human use which have not been tested for carcinogenic 
potential.  
Potential translational implications include a method for determining bioactivity 
of compounds in relation to carcinogenicity. Additionally, relative risk of exposure to 
mixtures could be determined via a developed CGDB which could assist in the 
development of cancer prevention guidelines and determining what level of chemical 
exposure is safe. 
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Future steps in increasing the breadth of impact for this method of developing 
carcinogenic signatures include:  
1) addition of multiple cell lines (including inducible pluripotent stem cells, 
iPSCs),  
2) the inclusion of carcinogen/carcinogen, carcinogen/non-carcinogen, and non-
carcinogen/non-carcinogen mixtures in the carcinogenome, and  
3) study of the different concentrations of chemical and changes in the genomic 
signature strength 
 
Studying different cell lines will allow the carcinogenome database to have broad 
applicability to a range of diseases and conditions. Using stem cells as a base cell line 
will assist in the development of patient-specific monitoring of gene regulation through 
the L1000 genomic signature readout. Such applications depend on the ability of the 
L1000 technology to precisely and accurately predict genome-wide changes across 
multiple cell lines.  
The second objective of including carcinogen/carcinogen, carcinogen/non-
carcinogen, and non-carcinogen/non-carcinogen mixtures in the carcinogenome will 
further extend the applicability of this technology. This will provide an extensive 
database to which scientists and physicians may turn to understand the effects of the 
previously 80,000 uncharacterized environmental chemicals to which humans are 
frequently exposed. 
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Potential correlations between different concentrations of chemical and changes 
in the genomic signature strength will play a critical role in increasing the strength of the 
captured genomic signatures. Although the dose concentrations used for these 
preliminary experiments were based on Pubmed searches of in vitro toxicity data for the 
individual compounds, it is likely that the optimal dose for a genomic signature will 
differ from the highest non-toxic dose. This signature-level genomic benchmark dose was 
introduced by Scott Auerbach, Ph.D., through his work on DrugMatrix (DM) and its 
application to cancer hazard characterization at the National Toxicology Program at 
NIEHS. Figure 12 demonstrates Auerbach’s findings of increased signature strength of a 
transcript with increasing dose concentration of a compound. 
 
 
 
Figure 12. Computational Genomic Models of Environmental and Chemical 
Carcinogenicity (as presented at Boston University October 25, 2012). 
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  In the future, these considerations will be incorporated into additional plate 
preparations. Further cell plates will be run in the near future to minimize the variability 
between triplicates, and in the additional PBS wash steps, through the methods discussed 
above. Then, this process will be used to capture genomic signatures in a replicable, high-
throughput procedure and will assist in the creation of a “carcinogenome” database 
(CGDB). 
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APPENDIX 
Appendix A: List of compounds included on Preliminary Plate  
1,2,3-propanetricarboxylic acid, 2-
hydroxy-3 
1,2-propylene glycol 
1,4-dioxane 
10-undecenal 
17 beta-estradiol 
17-beta-trenbolone 
2,3-benzofuran 
2,6-octadien-1-ol, 3,7-dimethyl-
,(2E)-3 
2-acetylaminofluorene 
2-nitrofluorene 
5-fluorouracil 
6-mercaptopurine monohydrate 
acetaldehyde, neat 
acetamide 
actinomycin D 
adriamycin, hydrochloride 
aflatoxin B1 
ampicillin trihydrate 
anethole 
azathioprine 
Benzo [e] pyrene B[e]P  
benzofuran 
benzoic acid 
B-estradiol 
beta testosterone 
bisphenol A 
cadmium chloride 
calcidefiol 
calcipotriene 
calcitriol 
carbaryl 
carbon tetrachloride 
Proprietary Compound 1 
Proprietary Compound 2 
CH223191 
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chlorambucil 
chlordecone (kepone) 
chloroform  
chlorotrianisene 
ciglitazone 
cis-Dichlorodiamine platinum 
cyclophosphamide monohydrate 
dexamethazone 
dieldrin 
diethylstilbestrol 
dimethylnitrosamine 
D-mannitol 
DMBA 
Emodin 
estriol 
ethinyl estradiol 
etoposide 
fluoxymesterone 
furan 
Geldanamycin 
Genistein 
glycerol 
hydrocortisone 
indol-3-carbinol (I3C) 
isoniazid 
isophosphamide 
L-ascorbic acid 
L-tryptophan 
melphalan 
methapyrilene hydrochloride 
methotrexate 
methoxychlor 
methyl testosterone 
monocrotaline 
monoethylhexylphthalate 
myleran 
n-nitrosodiethylamine 
oxymetholone 
paciltaxel 
pentachlorophenol, purified 
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podophyllotoxin 
SAHA 
silybin 
streptozotocin 
TCDD dioxin 
tetrachloroethylene 
tetracycline hydrochloride 
tranilast 
tributyl tin 
trichloroethylene 
triphenyl tin 
Troglitizone  
urethane 
vinblastine 
vincristine 
Wortmannin 
zearalenone 
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